Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Kunhong DengYi ZouChan ZouHong WangYuxia XiangXiaoyan YangShuang YangChang CuiGuo-Ping YangJie Huang

Published in: Cancer medicine (2022)

Compared with a single dose of SHR2554 50 mg, the exposure of SHR2554 in vivo was significantly affected by the combined administration of itraconazole.

Keyphrases

open label
phase iii
clinical trial
phase ii
study protocol
randomized controlled trial
double blind